Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06556680

EB-OCT Biopsy Guidance of Lung Cancer

Our objective is to develop, test, and validate a clinically robust polarization-sensitive optical coherence tomography (PS-OCT) biopsy guidance and diagnosis platform that is compatible with standard bronchoscopy techniques.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The goal of this study is to improve the unacceptably low diagnostic yield that is associated with low-risk bronchial biopsy. The investigators propose to do this by developing and optimizing a novel high-resolution optical coherence tomography (OCT) platform that will provide superior endomicroscopy images for biopsy guidance and in vivo diagnosis of lung cancer. OCT is a non-invasive imaging tool that rapidly generates high-resolution (< 10 µm) cross-sectional images of biological tissues with penetration depths approaching 2-3 mm. Polarization Sensitive OCT (PS-OCT) provides additional contrast to structural OCT by highlighting birefringent tissues such as collagen. When coupled with appropriate catheter designs OCT can be used to conduct in vivo microscopy of tissue microstructure including the detection and diagnosis of cardiovascular, gastrointestinal, and lung pathology.

The objective of this study is to develop, test, and validate a clinically robust PS-OCT biopsy guidance and diagnosis platform that is compatible with standard bronchoscopy techniques. Specifically, the investigators envision two clinical scenarios:

Biopsy Guidance:

Following the identification and gross localization of a nodule by low-dose computed tomography (LDCT), a low-risk transbronchial biopsy will be acquired for diagnosis. Placement of the biopsy catheter will be performed using standard approaches including bronchoscopy, electromagnetic navigation, or robotic bronchoscopy. The investigators will then conduct PS-OCT at the site to (1) confirm that the biopsy catheter is correctly positioned within the nodule, and (2) ensure that diagnostic-quality tissue is obtained.

OCT Diagnosis:

For small isolated pulmonary nodules in vivo OCT imaging may open up the possibility of diagnosis and treatment within the same procedure. For larger pulmonary nodules OCT images of the tissue microstructure may also be used to provide complementary information to pathologists and treating physicians to help make a clinical diagnosis particularly when biopsy samples are inadequate. OCT can image a much larger volume of the tumor microenvironment than is possible with standard bronchial biopsy acquisition.

The advantages of this new platform over existing OCT technology include novel endobronchial catheters that include metalenses in their design. These catheters provide OCT images at significantly higher resolution over a greater depth of penetration than traditional OCT catheters. Our OCT platform will also incorporate cutting-edge polarization-sensitive OCT (PS-OCT) imaging capabilities which investigators have demonstrated are necessary to distinguish between tumor and non-diagnostic tissues including tumor-associated scar. PS-OCT is challenging to perform catheter-based imaging and extremely computationally expensive when it incorporates accurate catheter calibration and processing. Our endobronchial OCT imaging system will provide real-time intra-procedural processing which is critical for OCT biopsy guidance and diagnosis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing elective lung biopsy for known or suspected malignancy in the lung
  • Patients must be over the age of 21
  • Patient must be able to give informed consent
  • Negative pregnancy test for all females of childbearing potential who are sexually active and not using contraception, are seeking to become pregnant, or are nursing

Exclusion criteria

  • Patients who are pregnant
  • The patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.

Treatment and study plan

optical coherence tomography

Device

In the OCT-guided biopsy arm, n=100 study subjects will be enrolled. The investigators will conduct biopsies and imaging using our newly developed OCT catheters and real-time image processing and display algorithms.

Primary outcomes

  1. Diagnostic yield of bronchial biopsy

    Time frame: 2 years

    EB-OCT guided bronchial biopsy changes the diagnostic yield when compared to traditional biopsy.

Secondary outcomes

  1. Determine the accuracy of OCT diagnosis of lung cancer in vivo by blinded reviewers.

    Time frame: 2 years

    As a secondary outcome the EB-OCT images will be reviewed by blinded readers following the completion of the study to determine the accuracy for the in vivo diagnosis of lung cancer by OCT images alone.

Study contacts

Contact information is provided by the study sponsor or research team.

Melissa J Suter, PhD

CONTACT

[email protected]

617-724-7691

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Official study title

Develop a High-resolution EB-OCT Platform to Visualize, Guide, Evaluate, and Increase the Accuracy of Lung Cancer Diagnosis in Human Subjects

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Aug 16, 2024
Registry last updated
Aug 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.